Stifel Nicolaus Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its target price cut by stock analysts at Stifel Nicolaus from $11.00 to $10.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 214.47% from the stock’s previous close.

NYXH has been the topic of a number of other reports. Cantor Fitzgerald upgraded shares of Nyxoah to a “strong-buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.33.

Nyxoah Stock Performance

Shares of NYXH traded up $0.09 during mid-day trading on Friday, hitting $3.18. 61,860 shares of the company’s stock were exchanged, compared to its average volume of 50,782. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40. Nyxoah has a fifty-two week low of $3.04 and a fifty-two week high of $11.87. The business’s 50 day moving average is $4.37 and its two-hundred day moving average is $4.86. The firm has a market capitalization of $108.31 million, a P/E ratio of -1.28 and a beta of 1.56.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Nyxoah had a negative net margin of 1,457.97% and a negative return on equity of 101.99%. The company had revenue of $6.62 million during the quarter, compared to analyst estimates of $5.70 million. On average, equities analysts expect that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

Institutional investors and hedge funds have recently made changes to their positions in the business. Heights Capital Management Inc. acquired a new position in shares of Nyxoah during the 4th quarter worth approximately $3,575,000. Franklin Resources Inc. raised its holdings in shares of Nyxoah by 0.9% in the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock worth $2,207,000 after acquiring an additional 2,655 shares during the last quarter. Rossmore Private Capital lifted its position in shares of Nyxoah by 12.6% in the third quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock valued at $616,000 after acquiring an additional 14,806 shares in the last quarter. Kovack Advisors Inc. lifted its position in shares of Nyxoah by 67.8% in the third quarter. Kovack Advisors Inc. now owns 97,039 shares of the company’s stock valued at $446,000 after acquiring an additional 39,212 shares in the last quarter. Finally, Shay Capital LLC acquired a new stake in shares of Nyxoah during the second quarter valued at $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.